Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Brian D. Jamieson"'
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Introduction: Few data have been published on the ethnic sensitivity of effectiveness, pharmacokinetics (PK), and pharmacodynamics (PD) of avatrombopag for the management of thrombocytopenia in patients with chronic liver disease (CLD). Methods: An e
Externí odkaz:
https://doaj.org/article/e79ac3d5944546308d1d8de72d981930
Publikováno v:
The Lancet. Haematology. 9(3)
Chemotherapy-induced thrombocytopenia is common and causes chemotherapy dose reductions or treatment delays, bleeding, and suboptimal oncological outcomes. We aimed to evaluate avatrombopag, a thrombopoietin receptor agonist that increases platelet c
Autor:
Kevin M. Watt, Andrea N. Edginton, Daniel Gonzalez, Christoph P. Hornik, Michael Cohen-Wolkowiez, Brian D. Jamieson, Sara Salerno
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:814-822
Solithromycin is a fluoroketolide antibiotic under investigation for community-acquired bacterial pneumonia (CABP). We developed a whole-body physiologically based pharmacokinetic (PBPK) model for solithromycin in adults using PK-Sim and MoBi version
Autor:
Dirkie Johanna Van Rensburg, Prabhavathi Fernandes, Carlos Barrera, Anita Das, Ismail Mitha, Pablo Alexis Doreski, Kay Clark, Kara Keedy, Jose Flores-Figueroa, Barbara Rewerska, Brian D. Jamieson, Amanda Sheets, David Oldach, Najumuddin Karimjee, Hristo Metev, Yuri Antonovsky, Joseph McDermott Molina, Cristina Mihaela Tanaseanu, Gary Horwith, Analia Mykietiuk, Mimi Floarea Nitu, Brian H. Rowe, Drusilla Scott
Publikováno v:
The Lancet Infectious Diseases. 16:421-430
Summary Background Community-acquired bacterial pneumonia (CABP) is a leading cause of morbidity and mortality, and treatment recommendations, each with specific limitations, vary globally. We aimed to compare the efficacy and safety of solithromycin
Autor:
Brian D. Jamieson, Christopher MacLauchlin, Stephen E Schneider, Kara Keedy, Prabhavathi Fernandes
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
Solithromycin, a novel macrolide and the first fluoroketolide, is being developed as a therapy for community-acquired bacterial pneumonia, with a distinct mechanism that provides activity against macrolide-resistant bacteria. The pharmacokinetics, me
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:4379-4386
Solithromycin, a new macrolide and the first fluoroketolide, is in late-stage clinical development and, like older macrolides, is primarily metabolized and excreted through liver-dependent mechanisms. This study evaluated the safety and pharmacokinet
Autor:
Sara N, Salerno, Andrea, Edginton, Michael, Cohen-Wolkowiez, Christoph P, Hornik, Kevin M, Watt, Brian D, Jamieson, Daniel, Gonzalez
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Solithromycin is a fluoroketolide antibiotic under investigation for community‐acquired bacterial pneumonia (CABP). We developed a whole‐body physiologically based pharmacokinetic (PBPK) model for solithromycin in adults using PK‐Sim and MoBi v
Autor:
Brian D. Jamieson, David W. Oldach, Kara Keedy, Meijian Zhou, Borje Darpo, Prabhavathi Fernandes, Philip T. Sager
Publikováno v:
The Journal of antimicrobial chemotherapy. 72(2)
Background Macrolide antibiotics may cause QT prolongation. Objectives To study the QT effect of a novel macrolide, solithromycin. Methods This was a thorough QT study with a three-way crossover design performed in healthy male and female subjects to
Autor:
Joven Gonong, Brian D. Jamieson, Thomas M. File, David N. Taylor, Violeta Vucinic-Mihailovic, Prabhavathi Fernandes, Barbara Rewerska, Anita Das, Amanda Sheets, David Oldach, Kara Keedy
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 63(8)
Background Solithromycin, a novel macrolide antibiotic with both intravenous and oral formulations dosed once daily, has completed 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia. Methods A total of 863 adults with com
Autor:
Cristina Mihaela Tanaseanu, Brian D. Jamieson, David Oldach, Carlos M. Luna, Peter Szabo, Kara Keedy, Prabhavathi Fernandes, Ismail Mitha, Alexis Doreski, Carlos Barrera, Anita Das
Publikováno v:
10.1 Respiratory Infections.
Rationale & Methods: Advanced age and underlying lung disease are risk factors for CABP morbidity. We evaluated a 4 th generation macrolide antibiotic, Solithromycin (S), vs Moxifloxacin (M) in a global, P3, DB-RCT for CABP of PORT II-IV severity. Ou